Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 3 , Pages 233-236 , May 2010

Prostate cancer screening and mortality: Comparison of recent randomized controlled clinical trials

References 

  1. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–916
  2. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: Does practice reflect the evidence?. JAMA. 2003;289:1414–1420
  3. Labrie F, Candas B, Cusan L, et al. Screening decreases prostate cancer mortality: 11-Year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. 2004;59:311–318
  4. Pinsky PF. Results of a randomized controlled trail of prostate cancer screening. Prostate. 2004;61:371
  5. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  6. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328
  7. Babaian RJ, Johnston DA, Naccarato W, et al. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: Relation to biopsy strategy. J Urol. 2001;165:757–760
  8. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452–1455
  9. Rembold CM. Number needed to screen: Development of a statistic for disease screening. BMJ. 1998;317:307–312
  10. Richardson A. Screening and the number needed to treat. J Med Screen. 2001;8:125–127
  11. Hardie C, Parker C, Norman A, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int. 2005;95:956–960
  12. Dall'Era MA, Konety BR, Cowan JE, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664–2670
  13. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006;24:46–50
  14. Torgerson DJ. Contamination in trials: Is cluster randomization the answer?. BMJ. 2001;322:355–357
  15. Altman DG, Whitehead J, Parmar MK, et al. Randomized consent designs in cancer clinical trials. Eur J Cancer. 1995;31A:1934–1944
  16. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185–191
  17. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: A review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin. 2008;58:161–179
  18. Mohler JL. Updating the prostate cancer guidelines. J Natl Compr Canc Netw. 2007;5:647–648
  19. Rosario DJ, Lane JA, Metcalfe C, et al. Contribution of a single repeat PSA test to prostate cancer risk assessment: Experience from the ProtecT study. Eur Urol. 2008;53:777–784

PII: S1078-1439(09)00364-0

doi: 10.1016/j.urolonc.2009.11.011

Urologic Oncology: Seminars and Original Investigations
Volume 28, Issue 3 , Pages 233-236 , May 2010

Article Tools